Mechelen, Belgium; 15 September 2008 – Galapagos NV (Euronext: GLPG) published today information as required by the new transparency legislation (Belgian Act of 2 May 2007).

Status on 15 September 2008

Basic data
Total share capital of Galapagos: €114,995,166.45
Total outstanding shares: 21,188,829 shares (each share represents one vote)
Total number of voting rights (the denominator): 21,188,829

Supplementary data
Total number of bonds convertible into securities conferring voting rights: zero
Total number of outstanding warrants that may become convertible into securities conferring voting rights: 2,239,867 (taking into account the 1:4 reverse split)
Total number of voting rights that may result from the exercise of outstanding warrants: 2,239,867
Total number of shares without voting rights: zero

Galapagos’ articles of association do not provide for additional thresholds for transparency notifications other than the legal threshold of 5% (and multiples thereof) set forth in the law. Shareholders who have already filed transparency notifications on shareholdings at or above 5% prior to 1 September 2008 are required by law to file an updated transparency notification by 25 October 2008 if their shareholding still equals or exceeds 5%.

Detailed information concerning the transparency legislation is available on the website of the Banking, Finance and Insurance Commission (CBFA). For submitting notifications, the CBFA recommends the use of the standard form TR-1 BE which is available from the CBFA website. The notifications should be transmitted to both the CBFA and Galapagos. For more information, please contact the Galapagos Investor Relations team (ir@glpg.com) or the CBFA.

About Galapagos
Galapagos (Euronext Brussels: GLPG; Euronext Amsterdam: GLPGA; OTC: GLPYY) is a drug discovery company with pre-clinical programs in bone and joint diseases and bone metastasis. Its BioFocus DPI division offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as chemogenomics and ADMET database products to select targets and compounds. Galapagos currently employs 500 people and operates facilities in six countries, with global headquarters in Mechelen, Belgium. More information about Galapagos and BioFocus DPI can be found at www.glpg.com and www.biofocusdpi.com.

CONTACT

Galapagos NV
Elizabeth Goodwin
Manager Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com